An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases

Abstract

Shown for reading. Its publisher allows quoting it, not republishing it.

References 35

1. 1.

   Eddy D. A manual for assessing health practices and designing practice guidelines. 1996.

   Not in our library

2. 2.

   American Gastroenterological Association policy statement on the use of medical practice guidelines by managed care organizations and insurance carriers. Gastroenterology. 1995;108:925-926.

   Not in our library10.1016/0016-5085(95)90469-7

3. 3.

   2011.

   Not in our library

4. 4.

   Shiffman RN, Shekelle P, Overhage JM, Slutsky J, Grimshaw J, Deshpande AM. Standardized reporting of clinical practice guidelines: a proposal from the Conference on Guideline Standardization. Ann Intern Med. 2003;139:493-498.

   Not in our library10.7326/0003-4819-139-6-200309160-00013

5. 5.

   Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958-965.

   Not in our library10.1016/s0140-6736(01)06102-5

6. 6.

   Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-982.

   Not in our library10.1056/nejmoa020047

7. 7.

   Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, for PEGASYS International Study Group, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346-355.

   Not in our library10.7326/0003-4819-140-5-200403020-00010

8. 8.

   Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, Zeuzem S, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med. 2007;147:677-684.

   Not in our library10.7326/0003-4819-147-10-200711200-00003

9. 9.

   Bruno S, Crosignani A, Facciotto C, Rossi S, Roffi L, Redaelli A, et al. Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study. Hepatology. 2010;51:2069-2076.

   Not in our library10.1002/hep.23528

10. 10.

    Morgan TR, Ghany MG, Kim HY, Snow KK, Shiffman ML, De Santo JL, Lee WM, Di Bisceglie AM, Bonkovsky HL, Dienstag JL, Morishima C, Lindsay KL, Lok AS. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology. 2010;52:833-844.

    Not in our library10.1002/hep.23744

11. 11.

    Kwo PY, Lawitz EJ, McCone J, Schiff ER, Vierling JM, Pound D, for SPRINT-,1 Investigators, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet. 2010;376:705-716.

    Not in our library10.1016/s0140-6736(10)60934-8

12. 12.

    Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, for SPRINT-,2 Investigators, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195-1206.

    Not in our library10.1056/nejmoa1010494

13. 13.

    Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, for HCV RESPOND-,2 Investigators, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1207-1217.

    Not in our library10.1056/nejmoa1009482

14. 14.

    McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, for PROVE,1 Study Team, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med. 2009;360:1827-1838.

    Not in our library10.1056/nejmoa0806104

15. 15.

    Hézode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, for PROVE, 2 Study Team, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med. 2009;360:1839-1850.

    Not in our library10.1056/nejmoa0807650

16. 16.

    Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, for ADVANCE Study Team, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405-2416.

    Not in our library10.1056/nejmoa1012912

17. 17.

    Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364:2417-2428.

    Not in our library10.1056/nejmoa1013086

18. 18.

    Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399-401.

    Not in our library10.1038/nature08309

19. 19.

    Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009;461:798-801.

    Not in our library10.1038/nature08463

20. 20.

    Foster GR, Hézode C, Bronowicki JP, Carosi G, Weiland O, Verlinden L, et al. Activity of telaprevir alone or in combination with peginterferon alfa-2a and ribavirin in treatment naïve genotype 2 and 3 hepatitis C patients: interim results of study C209. J Hepatol. 2009;50(suppl 1):S22.

    Not in our library

21. 21.

    Silva M, Kasserra C, Gupta S, Treitel M, Hughes E, O'Mara E, et al. Antiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2/3. Hepatol Int. 2011;5:3-558.

    Not in our library10.1016/j.jhep.2013.02.018

22. 22.

    Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, et al. Telaprevir in combination with peginterferon alfa 2a and ribavirin for 24 or 48 weeks in treatment-naive genotype 1 HCV patients who achived an extended rapid virological response: final results of Phase 3 ILLUMINATE study [Abstract LB-2]. Hepatology. 2010;52:401A.

    Not in our library

23. 23.

    Sulkowski MS, Poordad F, Manns MS, Bronowicki JP, Reddy KR, Harrison SA, et al. Anemia during treatment with peginterferon alfa-2b/ribavirin with or without boceprevir is associated with higher SVR rates: analysis of previously untreated and previous-treatment-failure patients. J Hepatol. 2011;54(suppl 1):S195-S196.

    Not in our library

24. 24.

    Sulkowski MS, Reddy R, Afdhal NH, Di Bisceglie AM, Zeuzem S, Poordad F, et al. Anemia had no effect on efficacy outcomes in treatment-naive patients who received telaprevir-based regimen in the ADVANCE and ILLUMINATE phase 3 studies. J Hepatol. 2011;54(suppl 1):S195.

    Not in our library

25. 25.

    Vierling JM, Kwo PY, Lawitz E, McCone J, Schiff ER, Pound D, et al. Frequencies of resistance-associated amino acid variants following combination treatment with boceprevir plus PEGINTRON (Peginterferon Alfa-2b)/ribavirin in patients with chronic hepatitis C, genotype 1 (G1) [Abstract]. Hepatology. 2010;52:702A.

    Not in our library

26. 26.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

27. 27.

    Zeuzem S, Sulkowski M, Zoulim F, Sherman KE, Albert A, Wei LJ, et al. Long-term follow-up of patients with chronic hepatitis C treated with telaprevir in combination with peginterferon alfa-2a and ribavirinterim analysis of the Extend study [Abstract]. Hepatology. 2010;52:436A.

    Not in our library

28. 28.

    Sarrazin C, Kieffer TL, Bartels D, Hanzelka B, Muh U, Welker M, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology. 2007;132:1767-1777.

    Not in our library10.1053/j.gastro.2007.02.037

29. 29.

    Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology. 2010;139:120-129.

    Not in our library10.1053/j.gastro.2010.04.013

30. 30.

    Mangia A, Thompson AJ, Santoro R, Piazzolla V, Tillmann HL, Patel K, et al. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology. 2010;139:821-827.

    Not in our library10.1053/j.gastro.2010.05.079

31. 31.

    Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009;41:1100-1104.

    Not in our library10.1038/ng.447

32. 32.

    Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41:1105-1109.

    Not in our library10.1038/ng.449

33. 33.

    Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, et al. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology. 2010;52:421-429.

    Not in our library10.1002/hep.23690

34. 34.

    Poordad F, Bronowicki JP, Gordon SC, Zeuzem S, Jacobson IM, Sulkowski M, et al. IL28B polymorphism predicts virological response in patients with chronic hepatitis C genotype 1 treated with boceprevir (BOC) combination therapy. J Hepatol. 2011;54(suppl 1):S6.

    Not in our library

35. 35.

    Jacobson IM, Catlett I, Marcellin P, Bzowej NH, et al. Telaprevir substantially improves SVR rates across all IL28b genotypes in the advanced trial. J Hepatol. 2011;54:S1369.

    Not in our library

Cited by papers we hold 6

• Adoption of direct-acting antiviral medications for hepatitis C: a retrospective observational study · 2019
  Not checked
• Effects on anemia of drug adjustment in patients with chronic hepatitis C during telaprevir-combined therapy · 2015
  Not checked
• The Spatial Distribution of Hepatitis C Virus Infections and Associated Determinants--An Application of a Geographically Weighted Poisson Regression for Evidence-Based Screening Interventions in Hotspots. · 2015
  Not checked
• Protease inhibitor-based triple therapy is highly effective for hepatitis C recurrence after liver transplant: a multicenter experience · 2014
  Not checked
• High-throughput screening (HTS) and hit validation to identify small molecule inhibitors with activity against NS3/4A proteases from multiple hepatitis C virus genotypes. · 2013
  Not checked
• The Molecular Basis of Drug Resistance against Hepatitis C Virus NS3/4A Protease Inhibitors · 2012
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.